WILLIAM CAMPBELL CROMWELL, M.D.
Marriage and Family Therapists in Raleigh, NC

Clinical Lipidology, Family Medicine

Lipoprotein & Metabolic Disorders Institute
8300 Health Park SUITE 320, Raleigh 27615
(919) 569-5971 (Phone), (919) 429-8143 (Fax)

carotid ultrasound

Arteriosclerosis, Cardiovascular (Heart & Blood Vessel) Disease, Cholesterol Disease, Dyslipidemia, Familial Hypercholesterolemia, High Blood Cholesterol, High Cholesterol, High Triglycerides, Hypercholesterolemia, Hypercholesterolemia Due To Arg3500 Mutation Of Apo B-100, Hypercholesterolemia Due To Ldl Receptor Deficiency, Hypercholesterolemia, Autosomal Dominant, Hypercholesterolemia, Autosomal Recessive, Hyperlipidemia, Hyperlipoproteinemia, Hyperlipoproteinemia Type 2, Hyperlipoproteinemia Type 3, Hyperlipoproteinemia Type 5, Lipid Disorder, Lipoprotein Disorder, Lipoproteinemia

Family Practice

Healthgrades Honor Roll, Fellow - National Lipid Association, 2011, Fellow - American Heart Association, 2005, Fellow - American Academy of Family Physicians, 1997, Mead Johnson Graduate Fellowship, 1989, Lipid and Lipoprotein Disorders: Current Clinical Solutions, 08/01/2012, Lipoprotein subfraction analysis using nuclear magnetic resonance spectroscopy (Book Chapter), 08/2007, Clinical utilization of lipoprotein subfractions (Book Chapter), 09/2007, Establishing and Managing A Private Practice Lipid Clinic, Second Edition, 09/2000, Lipid and Lipoprotein Disorders: Current Clinical Solutions, 10/2009, Clinical utilization of advanced lipid testing (Book Chapter), 07/2008, Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists., 09/2011, Measurement issues related to lipoprotein heterogeneity, 10/2002, Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia., 06/2011, Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia., 06/2011, Treatment of adults and children with familial hypercholesterolemia and evidence for recommendations., 2/5/2012, Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol less than 100 mg/dl, 10/2006, Low-density lipoprotein particle number and risk for cardiovascular disease, 09/2004, LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: Implications for LDL management, 12/2007, Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease, 11/2009, Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors, 11/2000, Cyclodextrin-adamantanecarboxylate inclusion complexes: studies of the variation in cavity size, 08/1985, Arterial age as a function of coronary artery calcium, 05/2009, HDL associations with coronary heart disease: Does measurement of cholesterol content give the best result?, 03/2007, Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy, 12/2006, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial., 03/2010

English

The Lipoprotein and Metabolic Disorders Institute (LMDI), PLLC is a clinical, educational and research organization that addresses the complexities of lipid (cholesterol and triglyceride) and lipoprotein (carriers of cholesterol and triglyceride) disorders. The clinical mission of this practice is to provide a center of excellence for comprehensive evaluation and management of genetic and acquired disorders affecting patients of all ages. Early detection of cardiovascular disease can lead to powerful preventive measures, including lifestyle modification and medical therapy. Using state of the art diagnostic and therapeutic measures we can help create individualized, integrated care plans designed to reduce risk of cardiovascular disease, both now and in the future.